DE602006017997D1 - Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel - Google Patents
Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechselInfo
- Publication number
- DE602006017997D1 DE602006017997D1 DE602006017997T DE602006017997T DE602006017997D1 DE 602006017997 D1 DE602006017997 D1 DE 602006017997D1 DE 602006017997 T DE602006017997 T DE 602006017997T DE 602006017997 T DE602006017997 T DE 602006017997T DE 602006017997 D1 DE602006017997 D1 DE 602006017997D1
- Authority
- DE
- Germany
- Prior art keywords
- fatch
- prophylactic
- deviations
- change
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005127523 | 2005-04-26 | ||
| PCT/JP2006/308695 WO2006118127A1 (ja) | 2005-04-26 | 2006-04-26 | 糖・脂質代謝異常の予防及び/又は治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602006017997D1 true DE602006017997D1 (de) | 2010-12-16 |
Family
ID=37307926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602006017997T Active DE602006017997D1 (de) | 2005-04-26 | 2006-04-26 | Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20090088442A1 (de) |
| EP (1) | EP1882474B1 (de) |
| JP (1) | JP5100375B2 (de) |
| KR (1) | KR101333876B1 (de) |
| CN (1) | CN101175494B (de) |
| AT (1) | ATE486604T1 (de) |
| BR (1) | BRPI0607680A2 (de) |
| CA (1) | CA2605847C (de) |
| DE (1) | DE602006017997D1 (de) |
| ES (1) | ES2355156T3 (de) |
| MX (1) | MX2007013301A (de) |
| WO (1) | WO2006118127A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2602259A3 (de) | 2005-02-18 | 2014-09-10 | Mitsubishi Tanabe Pharma Corporation | Salz des Prolinderivats, Solvat davon und Herstellungsverfahren dafür |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| JP5906086B2 (ja) | 2008-08-15 | 2016-04-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｆａｂ関連疾患の治療に用いるためのプリン誘導体 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| CN117547538A (zh) | 2009-02-13 | 2024-02-13 | 勃林格殷格翰国际有限公司 | 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| EP2514422B1 (de) * | 2009-12-18 | 2016-08-10 | Mitsubishi Tanabe Pharma Corporation | Teneligliptin präparat mit stabilisierter elution |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| MX366325B (es) | 2010-05-05 | 2019-07-05 | Boehringer Ingelheim Int | Terapia de combinacion. |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| HU227882B1 (hu) * | 2000-08-10 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | Prolinszármazékok és gyógyszerként való alkalmazásuk |
| CA2433090A1 (en) * | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| CZ20032321A3 (en) * | 2001-02-02 | 2004-03-17 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
| US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| WO2003101958A2 (en) * | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| EP2602259A3 (de) * | 2005-02-18 | 2014-09-10 | Mitsubishi Tanabe Pharma Corporation | Salz des Prolinderivats, Solvat davon und Herstellungsverfahren dafür |
-
2006
- 2006-04-26 WO PCT/JP2006/308695 patent/WO2006118127A1/ja active Application Filing
- 2006-04-26 AT AT06732351T patent/ATE486604T1/de not_active IP Right Cessation
- 2006-04-26 JP JP2007514757A patent/JP5100375B2/ja not_active Expired - Fee Related
- 2006-04-26 EP EP06732351A patent/EP1882474B1/de not_active Not-in-force
- 2006-04-26 ES ES06732351T patent/ES2355156T3/es active Active
- 2006-04-26 DE DE602006017997T patent/DE602006017997D1/de active Active
- 2006-04-26 MX MX2007013301A patent/MX2007013301A/es active IP Right Grant
- 2006-04-26 CA CA2605847A patent/CA2605847C/en active Active
- 2006-04-26 CN CN2006800142608A patent/CN101175494B/zh not_active Expired - Fee Related
- 2006-04-26 US US11/912,717 patent/US20090088442A1/en not_active Abandoned
- 2006-04-26 BR BRPI0607680-7A patent/BRPI0607680A2/pt not_active IP Right Cessation
- 2006-04-26 KR KR1020077027391A patent/KR101333876B1/ko not_active IP Right Cessation
-
2010
- 2010-08-11 US US12/854,538 patent/US20100305139A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE486604T1 (de) | 2010-11-15 |
| MX2007013301A (es) | 2008-03-07 |
| EP1882474B1 (de) | 2010-11-03 |
| ES2355156T3 (es) | 2011-03-23 |
| CN101175494B (zh) | 2011-07-13 |
| JPWO2006118127A1 (ja) | 2008-12-18 |
| CA2605847A1 (en) | 2006-11-09 |
| WO2006118127A1 (ja) | 2006-11-09 |
| KR20080010436A (ko) | 2008-01-30 |
| BRPI0607680A2 (pt) | 2009-09-22 |
| CA2605847C (en) | 2014-02-04 |
| JP5100375B2 (ja) | 2012-12-19 |
| EP1882474A4 (de) | 2008-07-09 |
| CN101175494A (zh) | 2008-05-07 |
| EP1882474A1 (de) | 2008-01-30 |
| US20090088442A1 (en) | 2009-04-02 |
| US20100305139A1 (en) | 2010-12-02 |
| KR101333876B1 (ko) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006017997D1 (de) | Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel | |
| HK1125855A1 (en) | Use of oligouronates for treating mucus hyperviscosity | |
| EP2322219A3 (de) | Verwendung von IL-23- und IL-17-Antagonisten zur Behandlung von Augenentzündungsautoimmunerkrankungen | |
| HK1121074A1 (en) | Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione | |
| ATE535257T1 (de) | Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin | |
| ATE536163T1 (de) | Verpackung für medizinische produkte und dergleichen | |
| NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
| SE0303571D0 (sv) | Medical product for moisture-sensitive medicaments | |
| HK1124552A1 (en) | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases | |
| ITMI20041317A1 (it) | Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento | |
| WO2007146426A3 (en) | Nanoshells for drug delivery | |
| IL186566A0 (en) | Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels | |
| WO2008060362A3 (en) | Methods and compositions for the treatment of skin diseases and disorders | |
| NO20074550L (no) | Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning | |
| WO2008155390A3 (en) | Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. | |
| DK1869185T3 (da) | Konjugat med P21-protein til kræftbehandling | |
| SG148120A1 (en) | An oral pharmaceutical and an oral care product | |
| CY1116166T1 (el) | Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori | |
| SE0401568D0 (sv) | A lock solution for medical devices, a device and a method for the application thereof | |
| ATE433459T1 (de) | Desoxo-nonadepsipeptide | |
| SG148117A1 (en) | Pharmaceuticals for treating or preventing oral diseases | |
| NO20074767L (no) | Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes | |
| ITAN20040031A1 (it) | Prodotto e metodo per la cura del diabete | |
| WO2008008507A3 (en) | Methods of treatment of diabetes | |
| ITRM20040625A1 (it) | Placca occlusiva personalizzata, per la cura di patologie posturali e relativo procedimento. |